home / stock / regn / regn quote
Last: | $896.82 |
---|---|
Change Percent: | -2.23% |
Open: | $913.97 |
Close: | $896.82 |
High: | $920.73 |
Low: | $891.46 |
Volume: | 501,688 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$896.82 | $913.97 | $896.82 | $920.73 | $891.46 | 501,688 | 04-19-2024 |
$893.99 | $901.26 | $893.99 | $908.81 | $891.67 | 450,630 | 04-18-2024 |
$901.19 | $903.88 | $901.19 | $911.6375 | $899.9 | 468,668 | 04-17-2024 |
$894.14 | $897.22 | $894.14 | $901.065 | $890.43 | 615,756 | 04-16-2024 |
$898.56 | $915.37 | $898.56 | $921.12 | $895.09 | 656,427 | 04-15-2024 |
$904.7 | $911.55 | $904.7 | $912.22 | $898.26 | 665,281 | 04-12-2024 |
$920.32 | $928.58 | $920.32 | $930.635 | $907.33 | 617,176 | 04-11-2024 |
$936.2 | $935.02 | $936.2 | $937.87 | $923.44 | 389,765 | 04-10-2024 |
$943.89 | $941.39 | $943.89 | $949.195 | $938 | 305,901 | 04-09-2024 |
$938.48 | $939.16 | $938.48 | $942.985 | $935.5101 | 330,917 | 04-08-2024 |
$942.7 | $939.31 | $942.7 | $949.83 | $934.87 | 363,545 | 04-05-2024 |
$937.02 | $962.2 | $937.02 | $962.2 | $935.36 | 410,837 | 04-04-2024 |
$950.95 | $955 | $950.95 | $961.68 | $950.43 | 413,251 | 04-03-2024 |
$954.68 | $961.44 | $954.68 | $961.44 | $951.02 | 438,124 | 04-02-2024 |
$969.31 | $964.73 | $969.31 | $970.2 | $954.09 | 360,696 | 04-01-2024 |
$962.49 | $970.38 | $962.49 | $970.79 | $959.25 | 461,867 | 03-29-2024 |
$962.49 | $970.38 | $962.49 | $970.79 | $959.25 | 461,867 | 03-28-2024 |
$966.3 | $971.04 | $966.3 | $976.75 | $962.41 | 314,755 | 03-27-2024 |
$963.55 | $961.99 | $963.55 | $966.68 | $957.775 | 386,837 | 03-26-2024 |
$961.09 | $954.01 | $961.09 | $964.98 | $952.4651 | 322,288 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess comp...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigat...
Tuesday, Amgen Inc (NASDAQ:AMGN) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in...